Systemic sclerosis (SSc) or scleroderma is a rare, systemic, autoimmune connective tissue disease. It causes increased collagen synthesis, leading to multi-organ sclerosis, including the skin and joints. Patients’ overall health and quality of life are harmed dramatically. Involvement of the face and, especially, the oral opening can limit patients’ ability to speak and eat, oral hygiene, and cosmetic appearance. Profhilo® (NAHYCO®) is an over-the-counter product consisting of pure hyaluronic acid. It is used to improve skin quality by increasing collagen production and adipocyte vitality. This interventional study evaluated the results of perioral injections of hyaluronic acid in terms of improved skin quality, elasticity, and increased oral opening. Patients diagnosed with SSc received an injection of one syringe of Profhilo® (2 mL of hyaluronic acid) at each of two clinic visits at one-month intervals. The oral opening was measured between the upper and lower central incisors before and after treatment. Quality of life was assessed using the modified Rodnan Skin Score and Health Assessment Questionnaire-Disability Index. A total of 14 patients received the first treatment, and 11 received the second treatment. The mean oral opening increased from 31.6 mm (range 17–50 mm) prior to therapy to 35.8 mm (range 21–56) 2 months following the second injection. Statistical analysis showed that there was a significant increase in the oral opening as observed one week (36.2 mm, p = 0.011), one month (36.2 mm, p = 0.007), and three months (31.6 mm, p = 0.023) after the second injection, at the 5-month follow-up. Treatment of SSc patients’ perioral area with Profhilo® can result in significant improvements in oral opening and quality of life.
Biofilm formation on prostheses and implanted devices can lead to serious complications and increased healthcare expenditures. Once formed, biofilm management is difficult and may involve a long course of antibiotics, additional surgery, and, occasionally, implant removal. This study evaluated the antibacterial properties of medical-grade silicone samples integrated with novel, non-leaching, antibacterial, quaternary ammonium silica (QASi) particles. Our collaborators (Nobio, Israel) prepared silicone sheets integrated with antibacterial QASi nanoparticles. Samples containing 0.5%, 0.75%, and 1%, QASi particles were evaluated for antibacterial properties against S. epidermidis, S. aureus, methicillin-resistant S. aureus (MRSA), E. faecalis, and P. aeruginosa using the direct contact test. The tested silicone samples integrated with QASi particles showed no bacterial growth, while growth was observed in control silicone samples without QASi. In addition, the agar diffusion test, used to evaluate the leaching of antibacterial components, exhibited no inhibition zone around the samples indicating that the QASi particles do not leach into surrounding milieu. The QASi nanoparticles exhibited very potent antibacterial surface properties, killing all viable bacteria placed on their surface. Incorporating QASi nanoparticle technology into medical products during production has the potential to create an antimicrobial surface that prevents microbial colonization and biofilm formation.
28 October 2026 in The American Journal of Cosmetic Surgery
Hyaluronic acid (HA) is a widely used dermal filler used for facial rejuvenation and contouring. Its use has expanded to off-label applications like breast augmentation, despite limited safety data and lack of regulatory approval for this indication. We present a single-patient case report of a severe complication following bilateral HA injection for breast augmentation. Clinical data were collected from the patient’s hospital course, laboratory results, imaging studies, intraoperative findings, microbiological cultures, and outpatient follow-up. A female patient presented several days after bilateral breast augmentation with HA injections, with bilateral breast swelling, erythema, pain, and signs of evolving sepsis. Imaging demonstrated extensive multiloculated fluid collections consistent with abscess formation. Intraoperative exploration revealed diffuse HA deposits mixed with purulent material and scattered necrotic breast tissue bilaterally. Although Sepsis-3 septic shock criteria were not fully met on arrival, the patient deteriorated perioperatively and subsequently required intensive care unit admission and vasopressor support. This case demonstrates the potential severity of complications following large-volume HA injection into the breast. The diffuse distribution of filler within breast tissue complicated complete removal and contributed to prolonged surgical and wound management. In addition to infection risk, HA breast injection may create diagnostic challenges in breast imaging and may result in long-term aesthetic deformity. Hyaluronic acid injection for breast augmentation may lead to severe, life-threatening complications. Given these risks, HA filler procedures should be strictly regulated and performed only within approved indications.
Mohs Micrographic Surgery (MMS) is considered the most conservative and preserving procedure for removing cutaneous tumors. The major disadvantage of MMS is that tumor involvement in tissue may be underestimated. This may lead to large excisions necessitating complex reconstruction with profound effects on cosmetic results. Some patients refuse complex reconstruction and demand simple closure of post-MMS skin defects. This retrospective cohort study describes our technique of serial Mohs excisions of large non-melanoma skin cancers for patients refusing flaps or skin graft reconstructions. A total of 51 patients who underwent MMS according to the described technique February 2020–May 2021 were included. The mean age was 76.5 (range 63–94) years and 55% were male. More than half of the lesions were on the nose. Mean lesion sizes were 14.25–55 mm depending on location. Most cases required two surgeries and only one needed a third surgery. Postsurgical defects were repaired using primary closure in 90% of cases. Mean follow-up was 31 months (range 6–48) with no evidence of local recurrence. In conclusion, this approach of serial excisions with MMS can be performed safely and achieve better cosmetic outcomes for patients presenting with large skin tumors of the face or other functionally important areas.